

# Handbook of Experimental Pharmacology

---

## *Volume 137*

### Editorial Board

G.V.R. Born, London

P. Cuatrecasas, Ann Arbor, MI

D. Ganten, Berlin

H. Herken, Berlin

K. Starke, Freiburg i. Br.

P. Taylor, La Jolla, CA

**Springer**

*Berlin*

*Heidelberg*

*New York*

*Barcelona*

*Hong Kong*

*London*

*Milan*

*Paris*

*Singapore*

*Tokyo*

# Novel Therapeutics from Modern Biotechnology

From Laboratory to Human Testing

## Contributors

A. Abuchowski, R.D. Armstrong, C.F. Bennett,  
J.A. Cavagnaro, D.L. Cole, S.B. Dillion, J.C. Erickson,  
D.E. Everitt, S.G. Griego, G.E. Hardee, T.K. Hart,  
S.P. Henry, H.E.J. Hofland, L. Huang, M.R. Koller,  
H. Kotani, R.J. Kreitman, A.A. Levin, A.S. Lubiniecki,  
J. Maluta, G.J. McGarrity, C.R. Middaugh, C.L. Nolan,  
M.L. Nucci, W.C. Ogier, I. Pastan, R. Pearlman, T.G. Porter,  
R.G. Scott, M.A. Serabian, P.J. Shadle, R.G.L. Shorr,  
T.M. Smith, G.S. Srivatsa, D.W. Zabriskie

## Editors

Dale L. Oxender and Leonard E. Post



Springer

DALE L. OXENDER, Ph.D.  
Cell Biology

LEONARD E. POST, Ph.D.  
Vice President, Discovery Research

Parke-Davis Pharmaceutical Research  
2800 Plymouth Road  
Ann Arbor, MI 48105  
USA

With 34 Figures and 19 Tables

ISBN 978-3-540-65927-3 Springer-Verlag Berlin Heidelberg New York

Library of Congress Cataloging-in-Publication Data

Novel therapeutics from modern biotechnology: from laboratory to  
humantesting / contributors, A. Abuchowski . . . [et al.]; editors,  
Dale L. Oxender and Leonard E. Post.

p. cm. – (Handbook of experimental pharmacology; v. 137)

Includes bibliographical references and index.

ISBN 978-3-540-65927-3 (hardcover: alk. paper)

1. Pharmaceutical biotechnology. I. Abuchowski, A. II. Oxender, Dale L.

III. Post, Leonard E., 1952– . IV. Series.

[DNLM: 1. Drug Design. 2. Drug Evaluation. 3. Biotechnology.

4. Technology, Pharmaceutical. W1HA51L v. 137 1999]

QP905.H3 vol. 137

[RS380]

615'.1s – dc21

[615'.19]

DNLM/DLC

for Library of Congress

98-41690

CIP

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

e-ISBN-13: 978-3-642-59990-3

DOI: 10.1007/978-3-642-59990-3

© Springer-Verlag Berlin Heidelberg 1999

Softcover reprint of the hardcover 1st edition 1999

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover design: *design & production* GmbH, Heidelberg

Typesetting: Best-set Typesetter Ltd., Hong Kong

Production Editor: Angélique Gcouta

SPIN: 10689474

27/3020 – 5 4 3 2 1 0 – Printed on acid-free paper

## Preface

A cover story of *Business Week Magazine* in January 1984 stated “Biotech Comes of Age”. In February 1986, *Venture Magazine* had a cover article entitled “The Biotech Revolution is Here”. This article went on to say “New Genetic Technologies Will Transform Our Lives”. These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed to commercialize the “New Biology”.

At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the “high-technology hype”, although companies are still forming as the technology advances.

A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotechnology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.

Although the “biotech” therapeutics represent unique scientific issues, there are now numerous examples that show that the principles of drug development apply to the newer systems as well as to development of novel small synthetic compounds. For example, there needs to be a well-controlled process for making the therapeutics, appropriate analytical methodologies to characterize the product, appropriate formulation to store and deliver the therapy to the patient, and a thorough characterization of the safety issues surrounding the new entity.

Our goal in this volume is to address the particular problems associated with several classes of biotechnology products and, at the same time, demonstrate that the principles are the same as in development of small new chemical entities. We have invited several scientists at biotechnology or pharmaceutical companies to share with us some of the unique problems that they encountered in getting biotech products into clinical trials and how they solved them.

The first chapter addresses FDA regulatory expectations for biotech products. The next several chapters discuss general issues common to each class of

biotech drug, such as proteins, peptides and nucleic acids. The balance of the chapters deals with specific biotech drugs that have successfully made it into clinical trials.

We would like to express our appreciation to the authors and the companies in which they work. The patience of the staff of Springer-Verlag is also appreciated. Special thanks goes to Joyce Peplinski for secretarial and organizational assistance.

D.L. OXENDER  
L.E. POST

# List of Contributors

ABUCHOWSKI, A., NPC Inc., 62 Bunnvale Road, Califon, NJ 01830, USA

ARMSTRONG, R.D., AASTROM Biosciences, Inc., P.O. Box 376, Ann Arbor, MI 48106, USA

BENNETT, C.F., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA

CAVAGNARO, J.A., Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA

COLE, D.L., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA

DILLON, S.B., Department of Molecular Virology and Host Defense, SmithKline Beecham Pharmaceuticals, Philadelphia, USA

ERICKSON, J.C., Biopharmaceutical Development, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA

EVERITT, D.E., Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals, Philadelphia, USA

GRIEGO, S.G., Department of Molecular Virology and Host Defense, SmithKline Beecham Pharmaceuticals, Philadelphia, USA

HARDEE, G.E., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA

HART, T.K., Department of Toxicology, SmithKline Beecham Pharmaceuticals, Philadelphia, USA

HENRY, S.P., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA

HOFLAND, H.E.J., RPR Gencell Corporation, 3825 Bay Center Place, Hayward, CA 94545, USA

- HUANG, L., Laboratory of Drug Targeting, Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
- KOLLER, M.R., AASTROM Biosciences, Inc., P.O. Box 376, Ann Arbor, MI 48106, USA
- KOTANI, H., Genetic Therapy, Inc. A Novartis Company, 938 Clopper Road, Gaithersburg, MD 20878, USA
- KREITMAN, R.J., Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 37/4E16, Bethesda, MD 20892, USA
- LEVIN, A.A., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA
- LUBINIECKI, A.S., Biopharmaceutical Development, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
- MALUTA, J., AASTROM Biosciences, Inc., P.O. Box 376, Ann Arbor, MI 48106, USA
- MCGARRITY, G.J., Genetic Therapy, Inc. A Novartis Company, 938 Clopper Road, Gaithersburg, MD 20878, USA
- MIDDAUGH, C.R., Department of Pharmaceutical Chemistry University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA
- NOLAN, C.L., Biopharmaceutical Development, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
- NUCCI, M.L., NPC Inc., 62 Bunnvale Road, Califon, NJ 01830, USA
- OGIER, W.C., AASTROM Biosciences, Inc., P.O. Box 376, Ann Arbor, MI 48106, USA
- PASTAN, I., Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 37/4E16, Bethesda, MD 20892, USA
- PEARLMAN, R., Megabios Corp., 863A Mitten Ave., Burlingame, CA 94010, USA
- PORTER, T. G., Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, Philadelphia, USA
- SCOTT, R.G., Biopharmaceutical Development, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA



SERABIAN, M.A., Center for Biologics Evaluation and Research (CBER),  
FDA, Rockville, MD 20852-1448, USA

SHADLE, P.J., Biopharmaceutical Development, SmithKline Beecham  
Pharmaceuticals, King of Prussia, PA 19406, USA

SHORR, R.G.L., Enzon Inc. 40 Kingsbridge Road, Piscataway, NJ, USA

SMITH, T.M., Biopharmaceutical Development, SmithKline Beecham  
Pharmaceuticals, King of Prussia, PA 19406, USA

SRIVATSA, G.S., Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad,  
CA 92008, USA

ZABRISKIE, D.W., Biopharmaceutical Development, SmithKline Beecham  
Pharmaceuticals, King of Prussia, PA 19406, USA  
*Present address:* Biogen Inc., Cambridge, MA 02139, USA

# Contents

## CHAPTER 1

### **Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials**

J.A. CAVAGNARO and M.A. SERABIAN .....	1
A. Introduction .....	1
B. Roles of Regulatory Scientists .....	2
C. Product Development and Availability .....	2
D. Data Requirements .....	4
E. Manufacturing .....	4
F. Preclinical Safety Testing .....	5
G. Case-By-Case Approach .....	6
H. Testing Goals .....	6
I. Study Design .....	7
J. Defining Exposure .....	7
K. Product-Specific Concerns .....	8
L. Accessibility of Preclinical Safety Data .....	9
M. Clinical Studies .....	10
I. Early Development .....	10
II. Late Development .....	10
N. Summary .....	11
References .....	11

## CHAPTER 2

### **Preparation of Clinical Trial Supplies of Biopharmaceuticals**

A.S. LUBINIECKI, J.C. ERICKSON, C.L. NOLAN, R.G. SCOTT, P.J. SHADLE, T.M. SMITH, and D.W. ZABRISKIE. With 1 Figure .....	13
A. Introduction .....	13
I. Research Support Systems .....	13
B. Preclinical Studies .....	13
C. Clinical Supplies .....	15
I. Fermentation .....	15
II. Harvest .....	17
III. Purification .....	18

D. Purification of rDNA-Derived Anti-RSV MAb .....	19
E. Product Quality Issues .....	22
I. Protein Purity .....	22
II. Protein Integrity .....	22
III. Microbial and Viral Safety .....	23
IV. Other Contaminants .....	23
F. Process Design and Validation .....	24
I. Validation of Endotoxin Removal .....	24
II. Process Validation of Model Virus Clearance .....	26
G. Process Economics and the Future of Chromatography .....	27
I. Process Automation and Control .....	27
II. Generic Purification Methods .....	30
H. Conclusions .....	31
References .....	31

### CHAPTER 3

#### **Proteins as Drugs: Analysis, Formulation and Delivery**

C.R. MIDDAGH and R. PEARLMAN .....	33
A. Introduction .....	33
B. The Analysis of Protein Pharmaceuticals .....	34
I. X-Ray Crystallography .....	36
II. Nuclear Magnetic Resonance .....	38
III. Mass Spectroscopy .....	39
IV. Multiple Parametric Approaches .....	40
V. Miscellaneous Comments .....	42
C. Formulation .....	44
D. Delivery .....	49
I. Controlled-Release Dosage Forms .....	51
II. A Practical Delivery Challenge: Insulin .....	52
References .....	54

### CHAPTER 4

#### **Strategies for Dealing With the Immunogenicity of Therapeutic Proteins**

M.L. NUCCI, R.G.L. SHORR, and A. ABUCHOWSKI .....	59
A. Introduction .....	59
B. Case Histories of Protein Therapeutic Development .....	61
I. Insulin .....	61
II. Growth Hormone .....	63
III. Asparaginase .....	64
IV. Glucocerebrosidase .....	65
V. OKT3 .....	66

C. Strategies Under Development for Increasing the Therapeutic Value of Proteins and Peptides .....	67
I. Encapsulation .....	67
II. Non-Parenteral Routes of Administration .....	70
III. Targeting .....	72
IV. Conjugation .....	75
V. Protein Engineering .....	77
D. Choosing the Proper Strategy for a Protein Therapeutic .....	79
E. The Future of Protein Therapeutics .....	80
References .....	80

CHAPTER 5

**Targeted Toxin Hybrid Proteins**

R.J. KREITMAN and I. PASTAN. With 6 Figures .....	89
A. Introduction .....	89
I. Protein Toxins That Inhibit Protein Synthesis .....	89
1. Plant Toxins .....	89
2. Bacterial Toxins .....	89
II. Structure and Function of Pseudomonas Exotoxin .....	90
1. Definition of Domains and Mechanism of Intoxication .....	90
2. Mutants Lacking Cell Binding .....	91
III. Types of Toxins Made with PE .....	91
1. Chemical Conjugates vs Recombinant Fusions. ....	91
2. Fusion Toxins Containing Transforming Growth Factor- $\alpha$ .....	91
3. Fusion Toxins Containing Interleukin 2 .....	92
4. Recombinant Immunotoxins .....	93
B. Preclinical Development of Anti-Tac(Fv) Toxins .....	93
I. Background .....	93
II. Efficacy Data on Relevant Human Cells .....	94
1. Human Activated T-Lymphocytes .....	94
2. Fresh Adult T-Cell Leukemia Cells .....	95
3. Fresh Chronic Lymphocytic Leukemia Cells .....	96
III. Efficacy Data in an Animal Model of IL2R-Bearing Cancer .....	97
1. Production of the Human ATAC-4 Line .....	97
2. Toxicity of Anti-Tac(Fv) Toxins in Mice .....	97
3. Pharmacokinetics in Mice .....	97
4. Antitumor Activity in Tumor-Bearing Mice .....	98
IV. Primate Testing .....	99
1. Pharmacokinetics in Cynomolgus Monkeys .....	99
2. Toxicity in Cynomolgus Monkeys .....	100
V. Production Issues .....	100

C. Preclinical Development of Interleukin 6-PE <sup>4E</sup> .....	102
I. Background .....	102
II. Study of IL6-PE <sup>4E</sup> For Ex Vivo Marrow Purging in Multiple Myeloma .....	102
1. Rationale .....	102
2. Efficacy Against Fresh Marrow Cells from Myeloma Patients .....	103
3. Safety Toward Fresh Normal Marrow Cells .....	103
4. Safety of IL6-PE <sup>4E</sup> Toward Normal Hematopoietic Progenitors .....	104
5. Lack of Prevention of Bone Marrow Engraftment .....	104
6. Carryover of IL6-PE <sup>4E</sup> In Vivo .....	104
III. Production of IL6-PE <sup>4E</sup> .....	105
D. Summary .....	105
References .....	106

## CHAPTER 6

### **SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection**

T.G. PORTER, S.G. GRIEGO, T.K. HART, D.E. EVERITT,  
and S.B. DILLON. With 4 Figures .....

111

A. Introduction .....	111
B. Early Challenges in the Development of SB 209763 .....	112
I. Selection of Target Antigen .....	112
II. Molecular Engineering of SB 209763 .....	113
III. Production .....	114
IV. Primary Structure Analysis .....	115
C. Preclinical Evaluation Prior to Testing in Humans .....	115
I. Fusion Inhibition: An In Vitro Correlate of Protection .....	116
II. Antigenic Variation .....	119
III. Animal Models of Respiratory Syncytial Virus Infection .....	119
IV. Safety and Pharmacokinetics .....	120
D. Challenges for the Early Clinical Development of SB 209763 .....	122
I. Selection of the Initial Study Population and Safety Considerations .....	122
II. Pharmacodynamic Markers to Establish Pharmacologic Effect .....	124
III. Formulation Considerations for Clinical Studies .....	124
IV. Surveillance for Anti-SB 209763 Antibodies .....	124
V. Transition to the Target Pediatric Population and Choice of Dose .....	125
VI. Results of Early Clinical Studies .....	125

Contents	XV
E. Conclusion	127
References	127

## CHAPTER 7

### **Preclinical Development of Antisense Therapeutics**

A.A. LEVIN, S.P. HENRY, C.F. BENNETT, D.L. COLE, G.E. HARDEE, and G.S. SRIVATSA. With 2 Figures	131
A. Introduction	131
B. Pharmacology of Antisense Oligodeoxynucleotides	131
I. Molecular Pharmacology of Antisense Oligodeoxynucleotides	131
II. In Vivo Pharmacology of Antisense Oligodeoxynucleotides	134
C. Pharmacokinetics and Toxicity of Oligodeoxynucleotide Therapeutics	136
I. Pharmacokinetics and Metabolism	136
II. Toxicity of Phosphorothioate Oligodeoxynucleotides	142
D. Chemistry, Manufacture and Control of Phosphorothioate Oligodeoxynucleotide Drugs	147
I. Synthesis of Phosphorothioate Oligodeoxynucleotides	149
1. Chemistry of Elongation	149
2. Chemistry of Sulfurization	150
3. <i>O,O</i> -Linked Phosphorothioate DNA Diastereoisomerism	151
II. Purification of Phosphorothioate Oligodeoxynucleotides	152
III. Quality Control of Phosphorothioate Oligodeoxynucleotides	153
E. Formulation and Drug Delivery of Oligodeoxynucleotides	154
I. Physical–Chemical Properties	154
II. Formulation	155
III. Drug Delivery: Targeting, Uptake and Release	156
F. Summary	157
References	157

## CHAPTER 8

### **Formulation and Delivery of Nucleic Acids**

H.E.J. HOFLAND and L. HUANG. With 6 Figures	165
A. Introduction	165
B. Formulation of DNA	166
I. Naked-DNA Injections	166
II. Gene Guns	167
III. Polymer-Based Formulations	167

IV. Lipid-Based Formulations .....	171
1. Liposome Encapsulation .....	171
2. Cationic Lipid/Nucleotide Complex .....	171
3. DNA-Binding Moiety .....	172
4. Hydrophobic Moiety .....	176
5. Spacer .....	177
6. Linker .....	177
7. Helper Lipid .....	178
C. Delivery to Target Cells .....	180
D. Cell Entry .....	182
I. Receptor-Mediated Uptake .....	182
E. Endosomal Release .....	183
F. Nuclear Localization .....	185
G. Gene Expression .....	186
References .....	187

## CHAPTER 9

### **Safe, Efficient Production of Retroviral Vectors**

H. KOTANI and G.J. MCGARRITY. With 11 Figures .....	193
A. Introduction .....	193
B. Vectors .....	194
I. Retroviral Vectors .....	194
C. Production of Retroviral Vectors .....	196
I. Production Methods .....	198
1. Batch Systems .....	198
2. Roller Bottles .....	198
3. Multilayered Propagator .....	200
II. Bioreactors .....	200
1. CellCube Bioreactor .....	200
2. Hollow-Fiber Bioreactor .....	201
3. Microcarrier Beads in Bioreactor .....	202
4. Packed-Bed Air-Lift Bioreactor .....	202
5. Serum-Containing Production .....	203
D. Downstream Processing .....	207
E. GMP Production of Retroviral Vectors .....	208
I. Cell Banking .....	209
II. Serum-Free Upstream Processing .....	211
III. Serum-Free Downstream Processing .....	211
F. In-Process Assays .....	212
G. Quality Control .....	215
H. Safety .....	215
I. Summary and Conclusions .....	217
References .....	218

CHAPTER 10

**Clinical Systems for the Production of Cells and Tissues  
for Human Therapy**

R.D. ARMSTRONG, M.R. KOLLER, J. MALUTA, and W.C. OGIER.

With 4 Figures .....	221
A. Introduction .....	221
B. Cell Therapy and Tissue Engineering .....	222
I. Ex Vivo Gene Therapy .....	223
II. Stem-Cell Therapy .....	223
C. Critical Requirements for Ex Vivo Cell Production .....	225
I. Process Reliability and Control: Automation .....	225
II. Process Sterility: Closed Systems .....	226
III. Cell Recovery .....	228
IV. Optimization of Key Culture Parameters by Design .....	228
V. Good Manufacturing Practices .....	230
D. Cell-Culture Devices and Procedures .....	231
I. Traditional Cell-Culture Processes:	
Research Laboratory Environment .....	232
1. Culture Flasks and Roller Bottles .....	233
2. Flexible Tissue Culture Containers .....	233
3. Bioreactors .....	234
II. AASTROM Cell-Production System .....	235
1. System Description .....	235
a. Disposable Cell Cassette .....	236
b. Incubator .....	237
c. Processor .....	237
d. System Manager .....	238
e. ID Key .....	238
E. Applications for On-Site Delivery of Therapeutic	
Cell Production .....	238
I. Bone-Marrow Cell Production .....	239
II. Other Cell and Tissue Production .....	239
F. Summary .....	240
References .....	240
<b>Subject Index</b> .....	243